<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35430085</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2402</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biological psychiatry</Title>
          <ISOAbbreviation>Biol Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Amygdala Noradrenergic System Is Compromised With Alcohol Use Disorder.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-3223(22)00090-7</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2022.02.006</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alcohol use disorder (AUD) is a leading preventable cause of death. The central amygdala (CeA) is a hub for stress and AUD, while dysfunction of the noradrenaline stress system is implicated in AUD relapse.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Here, we investigated whether alcohol (ethanol) dependence and protracted withdrawal alter noradrenergic regulation of the amygdala in rodents and humans. Male adult rats were housed under control conditions, subjected to chronic intermittent ethanol vapor exposure to induce dependence, or withdrawn from chronic intermittent ethanol vapor exposure for 2 weeks, and ex vivo electrophysiology, biochemistry (catecholamine quantification by high-performance liquid chromatography), in situ hybridization, and behavioral brain-site specific pharmacology studies were performed. We also used real-time quantitative polymerase chain reaction to assess gene expression of α<sub>1</sub><sub>B</sub>, β<sub>1</sub>, and β<sub>2</sub> adrenergic receptors in human postmortem brain tissue from men diagnosed with AUD and matched control subjects.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that α<sub>1</sub> receptors potentiate CeA GABAergic (gamma-aminobutyric acidergic) transmission and drive moderate alcohol intake in control rats. In dependent rats, β receptors disinhibit a subpopulation of CeA neurons, contributing to their excessive drinking. Withdrawal produces CeA functional recovery with no change in local noradrenaline tissue concentrations, although there are some long-lasting differences in the cellular patterns of adrenergic receptor messenger RNA expression. In addition, postmortem brain analyses reveal increased α<sub>1</sub><sub>B</sub> receptor messenger RNA in the amygdala of humans with AUD.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CeA adrenergic receptors are key neural substrates of AUD. Identification of these novel mechanisms that drive alcohol drinking, particularly during the alcohol-dependent state, supports ongoing new medication development for AUD.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Varodayan</LastName>
            <ForeName>Florence P</ForeName>
            <Initials>FP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California; Developmental Exposure Alcohol Research Center and Behavioral Neuroscience Program, Department of Psychology, Binghamton University, State University of New York, Binghamton, New York.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Reesha R</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California; Systems Neurobiology Laboratory, Salk Institute for Biological Studies, La Jolla, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matzeu</LastName>
            <ForeName>Alessandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wolfe</LastName>
            <ForeName>Sarah A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Curley</LastName>
            <ForeName>Dallece E</ForeName>
            <Initials>DE</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island; Neuroscience Graduate Program, Department of Neuroscience, Brown University, Providence, Rhode Island.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khom</LastName>
            <ForeName>Sophia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gandhi</LastName>
            <ForeName>Pauravi J</ForeName>
            <Initials>PJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rodriguez</LastName>
            <ForeName>Larry</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bajo</LastName>
            <ForeName>Michal</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Ambrosio</LastName>
            <ForeName>Shannon</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Core Laboratory, Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kerr</LastName>
            <ForeName>Tony M</ForeName>
            <Initials>TM</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Division of Pharmacology and Toxicology, University of Texas at Austin, Austin, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonzales</LastName>
            <ForeName>Rueben A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Division of Pharmacology and Toxicology, University of Texas at Austin, Austin, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leggio</LastName>
            <ForeName>Lorenzo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland; Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, Maryland; Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland; Department of Neuroscience, Georgetown University Medical Center, Washington, DC.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Natividad</LastName>
            <ForeName>Luis A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Division of Pharmacology and Toxicology, University of Texas at Austin, Austin, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haass-Koffler</LastName>
            <ForeName>Carolina L</ForeName>
            <Initials>CL</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island; Department of Psychiatry and Human Behavior, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Carney Institute for Brain Science, Brown University, Providence, Rhode Island; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martin-Fardon</LastName>
            <ForeName>Rémi</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roberto</LastName>
            <ForeName>Marisa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California. Electronic address: mroberto@scripps.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R00 AA025393</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 AA013498</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>F32 AA026765</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AA028549</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K01 AA023867</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 AA007456</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AA017447</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P60 AA006420</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AA021491</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AA026999</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K99 AA025393</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AA027760</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AA027700</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R00 AA025408</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AA029841</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AA015566</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 AA027614</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biol Psychiatry</MedlineTA>
        <NlmUniqueID>0213264</NlmUniqueID>
        <ISSNLinking>0006-3223</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adrenergic receptor</Keyword>
        <Keyword MajorTopicYN="N">Ethanol</Keyword>
        <Keyword MajorTopicYN="N">Norepinephrine/noradrenaline</Keyword>
        <Keyword MajorTopicYN="N">Prazosin</Keyword>
        <Keyword MajorTopicYN="N">Propranolol</Keyword>
        <Keyword MajorTopicYN="N">Translation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>20</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35430085</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biopsych.2022.02.006</ArticleId>
        <ArticleId IdType="pii">S0006-3223(22)00090-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
